About Us
Intelligent Drug Design
Qubigen is an exciting new venture that merges Presagen’s Federated AI technology and Qubist’s AI drug design and virtual screening capability.
Qubigen’s mission is to create a global federated AI system and computational toolbox for AI driven drug design.
Our Story
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse at est tortor. Morbi auctor et felis ornare molestie. Vestibulum hendrerit diam velit, et commodo mi viverra sit amet. Phasellus ac interdum enim. Proin et mauris ac mi vulputate vehicula.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse at est tortor. Morbi auctor et felis ornare molestie. Vestibulum hendrerit diam velit, et commodo mi viverra sit amet. Phasellus ac interdum enim.
Directors
Dr Amir Zalcenstein
Director
Managing Director, SYNthesis BioVentures
Dr Fabio Turatti
Director
Founding Partner & Managing Director of SYNthesis BioVentures.
CEO of SYNthesis Research.
Dr Jonathan Hall
Director
Founder & Managing Director of Qubigen
Prof Andrew Wilks
Director
Founding Partner & MD of SYNthesis BioVentures
James Roche
Director
Executive Director of Roche Holdings
Dr Michelle Perugini
Director and Chair of the Board
Head of Commercialisation &
CEO of UniSA Ventures
Senior Staff
Dr Jun Zeng
Founder & Chief Information Officer
Dr Tuc Nguyen
Senior AI Engineer
David Brooks
Product & Operations Manager
Dr Sonya Diakiw
Founder & Chief Scientific Officer
Andrew Murphy
Chief Technology Officer
Joshua Spender
Senior Software Engineer